Skip to main content
SpringerLink
Log in

PIPAC for Advanced Peritoneal Metastasis

  • Chapter
  • First Online:
Peritoneal Tumors and Metastases

  • 504 Accesses

Abstract

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a novel and advanced tool for the treatment of peritoneal metastasis. Due in part to the invasiveness of CRS/HIPEC and the often aggressive biology or advanced stage of peritoneal metastasis, it has become increasingly recognized that the risks of any intervention need to be carefully weighed against the potential benefit for the patient. PIPAC fills the gap between systemic chemotherapy and a locally aggressive surgical approach. PIPAC therefore can help facilitate a more personalized treatment for advanced peritoneal metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alyami M, Hübner M, Grass F, et al. Pressurized intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20:e368–77.

    Article  Google Scholar 

  2. Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy PIPAC. Ann Surg Oncol. 2013;20:2311–6.

    Article  Google Scholar 

  3. Chua TC, Pelz JO, Kerscher A, Morris DL, Esquivel J. Critical analysis of 33 patients with peritoneal carcinomatosis secondary to colorectal and appendiceal signet ring cell carcinoma. Ann Surg Oncol. 2009;16:2765–70.

    Article  Google Scholar 

  4. Chua TC, Morris DL, Esquivel J. Impact of the peritoneal surface disease severity score on survival in patients with colorectal cancer peritoneal carcinomatosis undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:1330–6.

    Article  Google Scholar 

  5. Dakwar GR, Shariati M, Willaert W, Ceelen W, De Smedt SC, Remaut K. Nanomedicine-based intraperitoneal therapy for the treatment of peritoneal carcinomatosis – Mission possible? Adv Drug Deliv Rev. 2016;108:13–24.

    Google Scholar 

  6. Demtröder C, Solass W, Winnekendonk G, Tempfer C, Reymond MA. Electrostatic Precipitation Pressurized IntraPeritoneal Aerosol Chemotherapy (ePIPAC): first in-human application. Pleura Peritoneum. 2016a;1:109–16.

    Article  Google Scholar 

  7. Demtröder C, Solass W, Zieren J, Strumberg D, Giger-Pabst U, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis. Color Dis. 2016b;18:364–71.

    Google Scholar 

  8. Elias D, Faron M, Iuga BS, et al. Prognostic similarities and differences in optimally resected liver metastases and peritoneal metastases from colorectal cancers. Ann Surg. 2015;261:157–63.

    Article  Google Scholar 

  9. Esquivel J, Piso P, Verwaal V, et al. American Society of Peritoneal Surface Malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer. J Surg Oncol. 2014;110:777–8.

    Article  Google Scholar 

  10. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17:1709–19.

    Article  Google Scholar 

  11. Freund M. On-label – off-label. Gibt es eine sicherheitsgarantie durch regulation? GGW. 2006;2006(4):22–30.

    Google Scholar 

  12. Girshally R, Demtröder C, Albayrak N, Zieren J, Tempfer C, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol. 2016;14:253–9.

    Article  Google Scholar 

  13. Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.

    Article  Google Scholar 

  14. Graversen M, Pedersen PB, Mortensen MB. Environmental safety during the administration of pressurized IntraPeritoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2016;1:203–8.

    Article  Google Scholar 

  15. Haidara A, El Balkhi S, Le Marchand, et al. Délivrer la chimiothérapie par pression et aérosol (PIPAC) est supérieure à la CHIP au plan experimental. Poster 198. Journées Francaises d’Onco-Hématologie Digestive, Paris 2016.

    Google Scholar 

  16. Hübner M, Teixeira H, Boussaha T, Cachemaille M, Lehmann K, Demartines N. PIPAC–pressurized intraperitoneal aerosol chemotherapy. A novel treatment for peritoneal carcinomatosis. Rev Med Suisse. 2015;11:1325–30.

    PubMed  Google Scholar 

  17. Jensen CT, Vicens-Rodriguez RA, Wagner-Bartak NA, et al. Multidetector CT detection of peritoneal metastases: evaluation of sensitivity between standard 2.5 mm axial imaging and maximum-intensity-projection (MIP) reconstructions. Abdom Imaging. 2015;40:2167–72.

    Article  Google Scholar 

  18. Jung DH, Son SY, Oo AM, et al. Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc. 2016;30:4258–64.

    Article  Google Scholar 

  19. Kakchekeeva T, Demtröder C, Herath NI, et al. In vivo feasibility of electrostatic precipitation as an adjunct to pressurized intraperitoneal aerosol chemotherapy (ePIPAC). Ann Surg Oncol. 2016;23(Suppl 5):592–8.

    Article  Google Scholar 

  20. Khomyakov V, Ryabov A, Ivanov A, et al. Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, Phase-2 study (PIPAC-GA2). Pleura Peritoneum. 2016;1:159–66.

    Article  Google Scholar 

  21. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Article  CAS  Google Scholar 

  22. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–18.

    Article  Google Scholar 

  23. Nadiradze G, Giger-Pabst U, Zieren J, Strumberg D, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg. 2016;20:367–73.

    Article  Google Scholar 

  24. Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41:1379–85.

    Article  CAS  Google Scholar 

  25. Oyais A, Solass W, Zieren J, Reymond MA, Giger-Pabst U. Occupational health aspects of pressurised intraperitoneal aerosol chemotherapy (PIPAC): confirmation of harmlessness. Zentralbl Chir. 2016;141:421–4.

    CAS  PubMed  Google Scholar 

  26. Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21:2608–14.

    Article  Google Scholar 

  27. Reymond MA, Hu B, Garcia A, et al. Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc. 2000;14:51–5.

    Article  CAS  Google Scholar 

  28. Reymond L, Solass W, Tempfer CB, Reymond MA. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): occupational health and safety management. Adv Exp Med Biol. 2015;87

    Google Scholar 

  29. Rezniczek GA, Jüngst F, Jütte H, et al. Dynamic changes of tumor gene expression during repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC) in women with peritoneal cancer. BMC Cancer. 2016;16:654–9.

    Article  Google Scholar 

  30. Robella M, Vaira M, De Simone M. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis. World J Surg Oncol. 2016;14:128.

    Article  Google Scholar 

  31. Roulin D, Hübner M, Allemann P, Demartines N. New developments of surgery in 2015. Rev Med Suisse. 2016;13:23–5.

    Google Scholar 

  32. Sabaila A, Fauconnier A, Huchon C. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): a new way of administration in peritoneal carcinomatosis of ovarian cancer. Gynecol Obstet Fertil. 2015;43:66–7.

    Article  CAS  Google Scholar 

  33. Schmid BC, Oehler MK. New perspectives in ovarian cancer treatment. Maturitas. 2014;77:128–36.

    Article  CAS  Google Scholar 

  34. Schneider MA, Eden J, Pache B, Laminger F, Lopez-Lopez V, Steffen T, Hübner M, Kober F, Roka S, Campos PC, Roth L, Gupta A, Siebenhüner A, Kepenekian V, Passot G, Gertsch P, Glehen O, Lehmann K. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg. 2018;268(5):845–53.

    Article  Google Scholar 

  35. Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26:847–52.

    Article  Google Scholar 

  36. Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20:3504–11.

    Google Scholar 

  37. Solass W, Giger-Pabst U, Demtröder C, Strumberg D, Zieren J, Reymond MA. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) in mesothelioma. In: Reymond MA, Solass W, editors. PIPAC pressurized intra-peritoneal aerosol chemotherapy – Cancer under pressure. Berlin Boston: De Gruyter; 2014a. p. 171–3.

    Google Scholar 

  38. Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014b;21:553–9.

    Google Scholar 

  39. Solass W, Sempoux C, Carr NY, Detlefsen S, Bibau F. Peritoneal sampling procedures and histological assessment of therapeutic response: Proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1:99–107.

    Article  Google Scholar 

  40. Tanis PJ. Is prevention of peritoneal dissemination the next step in the treatment of T4 colon cancer? Color Dis. 2016;18:125–6.

    Article  Google Scholar 

  41. Tempfer CB, Rezniczek GA, Ende P, Solass W, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. Anticancer Res. 2015a;35:6723–9.

    CAS  PubMed  Google Scholar 

  42. Tempfer CB, Winnekendonk G, Solass W, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. Gynecol Oncol. 2015b;137:223–8.

    Article  CAS  Google Scholar 

  43. U.S. National Institutes of Health. (A) A study with intraperitoneal cisplatin and doxorubicin in recurrent ovarian cancer and peritoneal carcinomatosis (NCT024757729). 2016a. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  44. U.S. National Institutes of Health. (B) Study with intraperitoneal cisplatin and doxorubicin in recurrent ovarian cancer and peritoneal carcinomatosis, NCT02475772. 2016b. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  45. U.S. National Institutes of Health. (C) Intraperitoneal aerosol chemotherapy in gastric cancer (PIPAC-GA01), NCT01854255. 2016c. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  46. U.S. National Institutes of Health. (D) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor (PARROT), NCT02735928. 2016d. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  47. U.S. National Institutes of Health. (E) Study of efficacy and safety of laparoscopic intra-abdominal chemotherapy (PIPAC) performed in patients with peritoneal carcinomatosis from colorectal, ovarian, gastric cancer and primary peritoneal tumors (PI-CaP), NCT02604784. 2016e. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  48. U.S. National Institutes of Health. (F) Treating peritoneal carcinomatosis with PIPAC, NCT02320448. 2016f. www.clinicaltrials.gov. Accessed 15 Oct 2016.

  49. Vaira M, Robella M, Borsano A, De Simone M. Single-port access for pressurized IntraPeritoneal aerosol chemotherapy (PIPAC): technique, feasibility and safety. Pleura Peritoneum. 2016;142:2275–80.

    Google Scholar 

  50. Zhao B, Lee SM, Lee HJ, et al. Variability in assessing treatment response: metastatic colorectal cancer as a paradigm. Clin Cancer Res. 2014;20:3560–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Transplantation, University Hospital Zurich, Zurich, Switzerland

    Kuno Lehmann, Lilian Roth & Joshua R. Kapp

  2. Institute of Pathology, University of Tübingen, Tübingen, Germany

    Wiebke Solass

  3. Department of Obstetrics and Gynecology, Marien Hospital Herne, Ruhr-Universität Bochum, Herne, Germany

    Clemens B. Tempfer

  4. Department of General, Visceral and Transplant Surgery, University of Tübingen, Tübingen, Germany

    Marc A. Reymond

  5. National Center for Pleura and Peritoneum (NCPP), University of Tübingen, Tübingen, Germany

    Marc A. Reymond

Authors
  1. Kuno Lehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wiebke Solass
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lilian Roth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joshua R. Kapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Clemens B. Tempfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc A. Reymond
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kuno Lehmann .

Editor information

Editors and Affiliations

  1. Department of Surgery, Charité – Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität of Berlin, Berlin, Germany

    Beate Rau

  2. Department of General, Visceral and Transplant Surgery, University Hospital of Tübingen, Comprehensive Cancer Center, Tübingen, Germany

    Alfred Königsrainer

  3. Basingstoke and North Hampshire Hospital, Peritoneal Malignancy Institute, Basingstoke, UK

    Faheez Mohamed

  4. Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, DC, USA

    Paul H. Sugarbaker

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lehmann, K., Solass, W., Roth, L., Kapp, J.R., Tempfer, C.B., Reymond, M.A. (2021). PIPAC for Advanced Peritoneal Metastasis. In: Rau, B., Königsrainer, A., Mohamed, F., Sugarbaker, P.H. (eds) Peritoneal Tumors and Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-62640-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62640-2_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62639-6

  • Online ISBN: 978-3-030-62640-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation